January 2006
Worldwide Biotech;Jan2006, Vol. 18 Issue 1, p7
Trade Publication
The article reports on the agreement between Depomed Inc. and Madaus Srl for the distribution and supply of ProQuin XR formulation of the antibiotic ciprofloxacin in Europe. Terms of the agreement are given. Depomed CEO John W. Fara offered a statement on the agreement. Background on the two companies is provided.


Related Articles

  • The Expanding Pill. Stone, Andy // Forbes Asia;10/17/2005, Vol. 1 Issue 5, p64 

    The article reports on the technique developed by pharmaceutical firm Depomed for keeping drugs in the stomach up to 12 hours before they fully dissolve. Its ingredient is polyethylene oxide, the same low-cost polymer that fluffs up toothpaste and soft-service ice cream. Depomed received U.S....

  • New blister packaging offered for once-daily UTI drug.  // Urology Times;6/1/2006, Vol. 34 Issue 7, p53 

    The article reports on the availability of new packaging of ciprofloxacin hydrochloride, an antibiotic used to treat bacterial infections in many different parts of the body, from Depomed, Inc. and Esprit Pharma in the U.S. The promotion is considered to be a convenient option to the original...

  • Horizon drops Depomed bid. Investor's Business Daily // Investors Business Daily;11/23/2015, pA02 

    The article reports that specialty pharmaceutical company Horizon Pharma has withdrawn its bid with specialty drug manufacturer Depomed. It mentions that the dropped out was due to the motion for injunctive relief granted to Depomed by the California court regarding the allegation Horizon's...

  • Santarus and Depomed Announce Settlement with Lupin of GLUMETZA Patent Litigation.  // Biomedical Market Newsletter;2/28/2012, Vol. 21, p1 

    The article reports that specialty biopharmaceutical companies Santarus Inc. and Depomed Inc. have entered into a settlement agreement with Lupin Ltd. to resolve pending patent litigation involving glumetza. The agreement grants Lupin the right to sell the genericversion of the drug under...

  • Depomed launches new postherpetic neuralgia drug.  // PharmaWatch: CNS;Nov2011, Vol. 10 Issue 11, p16 

    The article reports that Depomed Inc. has announced the availability of Gralise tablets as a once-daily treatment for postherpetic neuralgia (PHN) which is the pain following healing of rash associated with shingles.

  • GRALISE.  // MPR - Pharmacist's Edition;Winter2011/2012, Vol. 5 Issue 4, pA:4 

    The article offers brief information on Gralise gabapentin tablet for treatment of postherpic neuralgia from Depomed Inc.

  • Other News To Note.  // BioWorld Today;7/31/2013, Vol. 24 Issue 145, p2 

    This section offers news briefs on the biotechnology industry as of July 2013. A research agreement was signed by Antitope Ltd. with Faron Pharmaceuticals Ltd. to generate therapeutic monoclonal antibodies against the Clever-1 receptor. Array BioPharma Inc. has partnered with Celgene Corp. for...

  • Stock Movers.  // BioWorld Today;3/8/2010, Vol. 21 Issue 44, p2 

    A list of biotechnology companies, along with their stock changes as of March 5, 2010 is presented including Adamis Pharmaceuticals, Bioniche and Depomed Inc.

  • Other News To Note.  // BioWorld Today;3/30/2012, Vol. 23 Issue 62, p3 

    This section offers news briefs on the U.S. biopharmcautical sector including the preclinical data reported by CytRx Corp. on its combination therapy of doxorubicin and INNO-206, license fee payment received by Depomed Inc. from Boehringer Ingelheim GmbH, and the acquisition of MedEfficiency...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics